These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

82 related articles for article (PubMed ID: 1346414)

  • 1. Dermatan sulphate in haemodialysis.
    Lane DA; Ryan K; Ireland H; Curtis JR; Nurmohamed MT; Krediet RT; Roggekamp MC; Stevens P; ten Cate JW
    Lancet; 1992 Feb; 339(8789):334-5. PubMed ID: 1346414
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Antithrombotic properties of dermatan sulphate (MF 701) in haemodialysis for chronic renal failure.
    Ryan KE; Lane DA; Flynn A; Ireland H; Boisclair M; Shepperd J; Curtis JR
    Thromb Haemost; 1992 Nov; 68(5):563-9. PubMed ID: 1455403
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The haemorrhagic and antithrombotic effects of dermatan sulphate.
    Fernandez F; Van Ryn J; Ofosu FA; Hirsh J; Buchanan MR
    Br J Haematol; 1986 Oct; 64(2):309-17. PubMed ID: 3778825
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Increased sulphation improves the anticoagulant activities of heparan sulphate and dermatan sulphate.
    Ofosu FA; Modi GJ; Blajchman MA; Buchanan MR; Johnson EA
    Biochem J; 1987 Dec; 248(3):889-96. PubMed ID: 2963622
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Dermatan sulphate for the prevention of postoperative venous thromboembolism in patients with cancer. DOS (Dermatan sulphate in Oncologic Surgery) Study Group.
    Di Carlo V; Agnelli G; Prandoni P; Coccheri S; Gensini GF; Gianese F; Mannucci PM
    Thromb Haemost; 1999 Jul; 82(1):30-4. PubMed ID: 10456450
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Individualized anticoagulation with dermatan sulphate for haemodialysis in chronic renal failure.
    Boccardo P; Melacini D; Rota S; Mecca G; Boletta A; Casiraghi F; Gianese F
    Nephrol Dial Transplant; 1997 Nov; 12(11):2349-54. PubMed ID: 9394322
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Fibrin moderates the catalytic action of heparin but not that of dermatan sulfate on thrombin inhibition in human plasma.
    Okwusidi JI; Anvari N; Kulczycky M; Blajchman MA; Buchanan MR; Ofosu FA
    J Lab Clin Med; 1991 May; 117(5):359-64. PubMed ID: 2019790
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Dermatan sulfate and the prevention of experimental venous thrombosis].
    Desnoyers P; Bara L; Samama M
    Pathol Biol (Paris); 1989 Jun; 37(6):759-67. PubMed ID: 2674877
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Mechanisms for the anticoagulant effect of heparin and related polysaccharides.
    Ofosu FA
    Nouv Rev Fr Hematol (1978); 1988; 30(3):155-60. PubMed ID: 2971155
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Effect of oversulphated chondroitin and dermatan sulphate upon thrombin and factor Xa inactivation by antithrombin III or heparin cofactor II.
    Scully MF; Ellis V; Seno N; Kakkar VV
    Biochem J; 1988 Sep; 254(2):547-51. PubMed ID: 2902851
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Experimental studies on the relative efficacy of dermatan sulphate and heparin as antithrombotic agents.
    Merton RE; Thomas DP
    Thromb Haemost; 1987 Oct; 58(3):839-42. PubMed ID: 3433248
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Dermatan sulphate as an antithrombotic drug.
    Nenci GG
    Pathophysiol Haemost Thromb; 2002; 32(5-6):303-7. PubMed ID: 13679662
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Potentiation of the antithrombotic action of dermatan sulphate by small amounts of heparin.
    Thomas DP; Gray E; Merton RE
    Thromb Haemost; 1990 Oct; 64(2):290-3. PubMed ID: 2270536
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Is heparin the ideal anticoagulant for cardiopulmonary bypass? Dermatan sulphate may be an alternate choice.
    Brister SJ; Ofosu FA; Heigenhauser GJ; Gianese F; Buchanan MR
    Thromb Haemost; 1994 Apr; 71(4):468-73. PubMed ID: 8052965
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Antithrombotic properties of dermatan sulphate in a rat venous thrombosis model.
    Maggi A; Abbadini M; Pagella PG; Borowska A; Pangrazzi J; Donati MB
    Haemostasis; 1987; 17(6):329-35. PubMed ID: 3428718
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Oral administration of dermatan sulphate reduces venous thrombus formation in vivo: potential use as a formulation for venous thromboembolism.
    Osborne SA; Masci PP; Du QS; Daniel RA; Desilva K; Vitetta L; Zhao KN; Seymour RB
    Inflammopharmacology; 2021 Apr; 29(2):525-535. PubMed ID: 33230702
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Antithrombotic activity of dermatan sulphates, heparins and their combination in an animal model of arterial thrombosis.
    Iacoviello L; D'Adamo MC; Pawlak K; Polishchuck R; Wollny T; Buczko W; Donati MB
    Thromb Haemost; 1996 Dec; 76(6):1102-7. PubMed ID: 8972038
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The anticoagulant activity of dermatan sulphates: evidence against the involvement of antithrombin III.
    Kindness G; Long WF; Williamson FB
    Br J Pharmacol; 1981 Jan; 72(1):81-8. PubMed ID: 7225714
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The effects of dermatan sulfate at submicrogram/ml concentrations on in vitro thrombin generation.
    Delorme MA; Tam AS; Xu L
    Thromb Haemost; 1996 May; 75(5):747-51. PubMed ID: 8725717
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Unbalanced effects of dermatan sulfates with different sulfation patterns on coagulation, thrombosis and bleeding.
    Vicente CP; Zancan P; Peixoto LL; Alves-Sá R; Araújo FS; Mourão PA; Pavão MS
    Thromb Haemost; 2001 Nov; 86(5):1215-20. PubMed ID: 11816710
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.